CD4 and neoplasm: First, the ratio of Treg cells to the total CD4+ T cells in the tumor is higher than that of Treg cells in peripheral blood; second, PD-1 inhibition promotes the proliferation of Treg cells in non-responsive cancer patients and lastly, the depletion of Treg cells enhances anticancer immunity and slows tumor progression in mice and humans [8].